In the face of escalating antibiotic resistance, a new class of antibiotics is emerging from the innovative minds at Kinvard Bio, a Harvard startup aiming to combat drug-resistant infections.This groundbreaking advancement harnesses the principles of synthetic chemistry to create compounds that target the bacterial ribosome, a crucial site for antibiotic action.